[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633773":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":56,"collaborators":30,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":30,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":30,"enrollmentInfo":67,"targetDuration":30,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":78,"whyStopped":30,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Alcon Research","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free","EXPERIMENTAL","One drop in each eye on Day 1 (single dose)",[13],"Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free",{"label":15,"type":16,"description":11,"interventionNames":17},"Vehicle","PLACEBO_COMPARATOR",[18],"Drug: Vehicle",[20,27],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Investigational ophthalmic solution applied topically to the eye in a unit dose preservative free (UDPF) formulation",[9],[25,26],"FID 123472","Apraclonidine 0.125% UDPF",{"type":21,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Inactive ingredients of FID 123472 applied topically to the eye as an ophthalmic solution in a unit dose preservative free (UDPF) formulation",[15],null,[32],{"name":33,"affiliation":34,"role":35},"Clinical Trial Lead, Pharma","Alcon Research, LLC","STUDY_DIRECTOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":30,"email":41},"Alcon Call Center","CONTACT","1-888-451-3937","alcon.medinfo@alcon.com",[43],{"facility":44,"status":30,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":30},"Contact Alcon Call Center for Trial Locations","Fort Worth","Texas","76134","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-97.32085,32.72541,{"lat":54,"lon":53},{"type":57,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100633773","phase-3-efficacy-and-safety-of-fid-123472-ophthalmic-solution-for-ocular-redness-in-adults-100633773",false,"NCT07531043","Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults","A Two-Arm Multicenter Clinical Trial to Investigate Efficacy and Safety of FID123472 Ophthalmic Solution Compared With Vehicle in Adult Subjects With Ocular Redness","Key Inclusion Criteria:\n\n* Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form.\n* Willing and able to follow all instructions and attend all study visits.\n* History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion.\n* Baseline investigator-assessed ocular redness score of greater than 1 on a 5-point scale in both eyes prior to randomization on Day 1 (Visit 2).\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Known contraindications or sensitivity to the use of any of the investigational product(s) or their components, or any other medication required by the protocol.\n* Ocular surgical intervention within 6 months prior to Visit 1 or during the study.\n* Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study specific parameters.\n* Use of any of the prohibited medications or devices as specified in the study protocol.\n* Out-of-range vital signs (blood pressure and\u002For pulse rate) as defined in the study protocol.\n* Abnormal intraocular pressure.\n* Other protocol-defined exclusion criteria may apply.","ALL","18 Years",{"count":68,"type":69},230,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.",[75],"Ocular Hyperemia",[77],"Ocular Redness","NOT_YET_RECRUITING","2026-06-08",{"date":81,"type":82},"2026-06-10","ACTUAL",{"date":84,"type":69},"2026-10",{"date":86,"type":69},"2027-02",{"name":5,"class":6},1]